Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Stero Biotechs Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04439955
- Locations
- ๐ฎ๐ฑ
Meir Medical Center, Kfar Saba, Israel
A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Stero Biotechs Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT04129489
- Locations
- ๐ฎ๐ฑ
Belinson Medical Center, Petach Tikva, Israel
A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
Phase 2
Completed
- Conditions
- Steroid Dependent Crohn's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Stero Biotechs Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04056442
- Locations
- ๐ฎ๐ฑ
Soroka Medical Center, Beer Sheva, Israel
๐ฎ๐ฑShamir Medical Center, Tzrifin, Israel
๐ฎ๐ฑMeir Medical Center, Kfar Saba, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath